NeuroScience Research Center, LLC.
Previous Clinical Trials
UCB BIOPHARMA SPRL EP0093
10/2019-05/2020
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
UCB BIOPHARMA SPRL EP0092
05/2019-05/2020
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
EMD SERONO MS200527-0074
01/2020-03/2020
A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED STUDY OF EVOBRUTINIB COMPARED WITH AN INTERFERON BETA LA (AVONEX®), IN PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS TO EVALUATE EFFICACY AND SAFETY
GLOBAL KINETICS Pty Ltd (GKC)
01/2020-03/2020
UTILIZATION OF TARGET RANGES TO TREAT PATIENTS WITH PARKINSON’S DISEASE BY OBJECTIVE MEASUREMENT USING THE PERSONAL KINETIGRAPH® (PKG®) COMPARED TO STANDARD OF CARE ASSESSMENT (TARGET-PD)- A RANDOMIZED CONTROLLED TRIAL
TETRA DISCOVERY PARTNERS, INC BPN14770-CNS-201
09/2019-10/2019
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,3-ARM PARALLEL DESIGN STUDY TO EVALUATE THE EFFECTS OF BPN14770 IN PATIENTS WITH EARLY STAGE ALZHEIMER’S DISEASE
OTSUKA PHARMACEUTICAL 405-201-00015
03/2019-01/2020
AN OPEN LABEL, 52 WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
EISAI E2609-G000-301
02/2017-12/2019
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE
EISAI E2609-G000-202
01/2016-12/2019
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED, PROOF-OF-CONCEPT, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF E2609 IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL ALZHEIMER’S DISEASE) AND MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE (REVISED PER AMENDMENT 01)
ALKERMES ALK8700-A301
05/2016-12/2019
A PHASE 3 OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ALKS 8700 IN ADULTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
ALKERMES ALK8700-A302
05/2017-07/2019
A PHASE 3 STUDY IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TO EVALUATE THE TOLERABILITY OF ALKS 8700 AND DIMETHYL FUMARATE
SUVEN LIFE SCIENCES LTD CTP2S1502HT6
02/2016-07/2019
A PHASE 2A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 26-WEEK, PLACEBO-CONTROLLED STUDY OF 50 MG AND 100 MG OF SUVN-502 IN SUBJECTS WITH MODERATE ALZHEIMER’S DISEASE CURRENTLY TREATED WITH DONEPEZIL HYDROCHLORIDE AND MEMANTINE HYDROCHLORIDE
MERCK 8931-019
04/2014-05/2018
A PHASE II/III RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK 8931 IN SUBJECT WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL AD)
F. HOFFMANN-LA ROCHE LTD BN29553
08/2017-02/2018
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE
BIOGEN 109MS401 (ESTEEM)
04/2014-08/2017
A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION OF TECFIDERA (DIMETHYL FUMARATE) WHEN USED IN A ROUTINE MEDICAL PRACTICE IN THE TREATMENT OF MULTIPLE SCLEROSIS (ESTEEM)
MERCK 8931-017
02/2015-06/2017
A RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND EFFICACY AND SAFETY TRIAL OF MK-8931 IN SUBJECTS MILD TO MODERATE ALZHEIMER’S DISEASE
NOVARTIS COMB157G2301
11/2016-06/2017
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
VTV THERAPEUTICS LLC TTP488-301
02/2017-04/2017
RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE
ALLERGAN CGP-MD-01
11/2016-03/2017
PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION
MARINUS
11/2015- 06/2016
PROTOCOL 1042-0604 A FOLLOW-ON, TWO-YEAR OPEN-LABEL EXTENSION STUDY OF GANAXOLONE AS ADD-ON THERAPY IN ADULT PATIENTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES
ACORD MARINUS
02/2014-06/2016
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF GANAXOLONE AS ADJUNCTIVE THERAPY FOR ADULTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT #1042-0603
NOVARTIS CFTY720DUS09
06/2012-06/2015
A 12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (PREFERMS)
PFIZER A0081105
08/2013-01/2015
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC CLONIC SEIZURE
BIOGEN 109MS404 (RESPOND)
03/2014-01/2015
A MULTI-CENTER, OPEN-LABEL, 12 MONTH OBSERVATIONAL STUDY EVALUATING THE CLINICAL EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES OF ORAL TECFIDERA (DIMETHYL FUMARATE) DELAYED-RELEASE CAPSULES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS AFTER SUBOPTIMAL RESPONSE TO GLATIRAMER ACETATE
A (DALF-PS-1016)
11/2014-2014
A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGTHS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POST-ISCHEMIC STROKE (MILESTONE)
BIOGEN 105MS401 (POP)
12/2014
PLEGRIDY (PEGINTERFERON β-1A) REAL WORLD EFFECTIVENESS AND SAFETY OBSERVATIONAL PROGRAM
AVANIR PHARMACEUTICALS, INC
02/2014-11/2014
A STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF NUEDEXTA (DEXTROMETHORPHAN 20MG/QUINIDINE 10MG) IN THE TREATMENT OF PSEUDOBULBAR AFFECT(PBA)
LABRYS BIOLOGICS
03/2014-10/2014
A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL-GROUP, STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF HIGH FREQUENCY EPISODIC MIGRAINE
UCB N01358
08/2013-02/2014
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (> 16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES
UCB N01379
08/2013-02/2014
AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY
ALLERGAN GMA-BTX-CM-10-001
03/2013-06/2013
AN OPEN LABEL, MULTICENTER STUDY OF THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF BOTOX (ONABOTULINUMTOXINA) FOR THE PROPHYLAXIS OF HEADACHES IN ADULT PATIENTS WITH CHRONIC MIGRAINE (THE COMPEL STUDY)
UCB SP0980 (VIMPAT)
05/2012-06/2013
A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATORY STUDY TO EVALUATE THE TOLERABLITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES
NOVARTIS CFTY720DUS01
11/2010-10/2011
A 6 MONTH, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTI-CENTER, STUDY TO EVALUATE PATIENT OUTCOMES, SAFETY AND TOLERABILITY OF FINGOLIMOD/DAY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO ARE CANDIDATES FOR MS THERAPY CHANGE FROM PREVIOUS DISEASE MODIFYING THERAPY (EPOC)
10/2019-05/2020
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
UCB BIOPHARMA SPRL EP0092
05/2019-05/2020
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
EMD SERONO MS200527-0074
01/2020-03/2020
A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED STUDY OF EVOBRUTINIB COMPARED WITH AN INTERFERON BETA LA (AVONEX®), IN PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS TO EVALUATE EFFICACY AND SAFETY
GLOBAL KINETICS Pty Ltd (GKC)
01/2020-03/2020
UTILIZATION OF TARGET RANGES TO TREAT PATIENTS WITH PARKINSON’S DISEASE BY OBJECTIVE MEASUREMENT USING THE PERSONAL KINETIGRAPH® (PKG®) COMPARED TO STANDARD OF CARE ASSESSMENT (TARGET-PD)- A RANDOMIZED CONTROLLED TRIAL
TETRA DISCOVERY PARTNERS, INC BPN14770-CNS-201
09/2019-10/2019
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,3-ARM PARALLEL DESIGN STUDY TO EVALUATE THE EFFECTS OF BPN14770 IN PATIENTS WITH EARLY STAGE ALZHEIMER’S DISEASE
OTSUKA PHARMACEUTICAL 405-201-00015
03/2019-01/2020
AN OPEN LABEL, 52 WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
EISAI E2609-G000-301
02/2017-12/2019
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE
EISAI E2609-G000-202
01/2016-12/2019
A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED, PROOF-OF-CONCEPT, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF E2609 IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL ALZHEIMER’S DISEASE) AND MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE (REVISED PER AMENDMENT 01)
ALKERMES ALK8700-A301
05/2016-12/2019
A PHASE 3 OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ALKS 8700 IN ADULTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
ALKERMES ALK8700-A302
05/2017-07/2019
A PHASE 3 STUDY IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TO EVALUATE THE TOLERABILITY OF ALKS 8700 AND DIMETHYL FUMARATE
SUVEN LIFE SCIENCES LTD CTP2S1502HT6
02/2016-07/2019
A PHASE 2A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 26-WEEK, PLACEBO-CONTROLLED STUDY OF 50 MG AND 100 MG OF SUVN-502 IN SUBJECTS WITH MODERATE ALZHEIMER’S DISEASE CURRENTLY TREATED WITH DONEPEZIL HYDROCHLORIDE AND MEMANTINE HYDROCHLORIDE
MERCK 8931-019
04/2014-05/2018
A PHASE II/III RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK 8931 IN SUBJECT WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL AD)
F. HOFFMANN-LA ROCHE LTD BN29553
08/2017-02/2018
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE
BIOGEN 109MS401 (ESTEEM)
04/2014-08/2017
A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION OF TECFIDERA (DIMETHYL FUMARATE) WHEN USED IN A ROUTINE MEDICAL PRACTICE IN THE TREATMENT OF MULTIPLE SCLEROSIS (ESTEEM)
MERCK 8931-017
02/2015-06/2017
A RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND EFFICACY AND SAFETY TRIAL OF MK-8931 IN SUBJECTS MILD TO MODERATE ALZHEIMER’S DISEASE
NOVARTIS COMB157G2301
11/2016-06/2017
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
VTV THERAPEUTICS LLC TTP488-301
02/2017-04/2017
RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE
ALLERGAN CGP-MD-01
11/2016-03/2017
PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION
MARINUS
11/2015- 06/2016
PROTOCOL 1042-0604 A FOLLOW-ON, TWO-YEAR OPEN-LABEL EXTENSION STUDY OF GANAXOLONE AS ADD-ON THERAPY IN ADULT PATIENTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES
ACORD MARINUS
02/2014-06/2016
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF GANAXOLONE AS ADJUNCTIVE THERAPY FOR ADULTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT #1042-0603
NOVARTIS CFTY720DUS09
06/2012-06/2015
A 12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (PREFERMS)
PFIZER A0081105
08/2013-01/2015
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC CLONIC SEIZURE
BIOGEN 109MS404 (RESPOND)
03/2014-01/2015
A MULTI-CENTER, OPEN-LABEL, 12 MONTH OBSERVATIONAL STUDY EVALUATING THE CLINICAL EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES OF ORAL TECFIDERA (DIMETHYL FUMARATE) DELAYED-RELEASE CAPSULES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS AFTER SUBOPTIMAL RESPONSE TO GLATIRAMER ACETATE
A (DALF-PS-1016)
11/2014-2014
A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGTHS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POST-ISCHEMIC STROKE (MILESTONE)
BIOGEN 105MS401 (POP)
12/2014
PLEGRIDY (PEGINTERFERON β-1A) REAL WORLD EFFECTIVENESS AND SAFETY OBSERVATIONAL PROGRAM
AVANIR PHARMACEUTICALS, INC
02/2014-11/2014
A STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF NUEDEXTA (DEXTROMETHORPHAN 20MG/QUINIDINE 10MG) IN THE TREATMENT OF PSEUDOBULBAR AFFECT(PBA)
LABRYS BIOLOGICS
03/2014-10/2014
A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL-GROUP, STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF HIGH FREQUENCY EPISODIC MIGRAINE
UCB N01358
08/2013-02/2014
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (> 16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES
UCB N01379
08/2013-02/2014
AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY
ALLERGAN GMA-BTX-CM-10-001
03/2013-06/2013
AN OPEN LABEL, MULTICENTER STUDY OF THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF BOTOX (ONABOTULINUMTOXINA) FOR THE PROPHYLAXIS OF HEADACHES IN ADULT PATIENTS WITH CHRONIC MIGRAINE (THE COMPEL STUDY)
UCB SP0980 (VIMPAT)
05/2012-06/2013
A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATORY STUDY TO EVALUATE THE TOLERABLITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES
NOVARTIS CFTY720DUS01
11/2010-10/2011
A 6 MONTH, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTI-CENTER, STUDY TO EVALUATE PATIENT OUTCOMES, SAFETY AND TOLERABILITY OF FINGOLIMOD/DAY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO ARE CANDIDATES FOR MS THERAPY CHANGE FROM PREVIOUS DISEASE MODIFYING THERAPY (EPOC)
